Inve India ▾

Akums Drugs share price & results

Akums Drugs· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

India's largest CDMO by revenue, capacity and clients, also making branded formulations and APIs.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue1,167 ₹ crore+14.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin15.0 %+2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit101 ₹ crore+55.4% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity9.58 %−8.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin21.98 %+17.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)9.22 %+7.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 9 judged targets kept · 11 open · verdicts reflect calls analysed to Q1 FY27.

Akums Drugs management guidance track record on Inve: 20 targets tracked across analysed earnings calls (4 achieved, 5 missed, 11 open).

TargetOriginal wordingSaidLatest callVerdict
API Segment ProfitabilityBreakeven in 1 to 2 years
Call transcript, Q3 FY25 · 7 Feb 2025		Q3 FY25Q1 FY27:Original promise remains missed. Management has issued a new, more specific target to be monthly EBITDA positive by Feb-Mar 2027.
Call transcript, Q1 FY27 · 10 Aug 2026		Missed
Zambia JV Supply RevenueUS$50 million over the next two years
Call transcript, Q2 FY26 · 17 Nov 2025		Q2 FY26Q1 FY27:Timeline further clarified to 'likely be in Q3 and maybe some parts in Q4' of FY27, a slight pushback from 'end of Q2 FY27'.
Call transcript, Q1 FY27 · 10 Aug 2026		Delayed
EU CDMO Contract Annual RevenueINR 300-350 crores steady state FY28 onwards
Call transcript, Q4 FY25 · 27 May 2025		Q4 FY25Q1 FY27:Management confirmed they will 'kickstart our European business' within the next financial year (FY28), keeping the project on its stated timeline.
Call transcript, Q1 FY27 · 10 Aug 2026		On Track

Source: Inve Guidance Tracker for Akums Drugs · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Akums Drugs's 20 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 17 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹719.25 +4.76% · +₹32.65

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +56.2% 1Y

₹400₹500₹600₹700₹800Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 17 Nov 2025Q3 FY26 — 16 Feb 2026Q4 FY26 — 18 May 2026Q1 FY27 — 10 Aug 2026

1Y: ₹460.55 on 24 Oct 2025 → ₹719.25. High ₹823.3 (23 Sept 2026), low ₹414.05 (24 Nov 2025).

Previous close
₹686.6
Market cap
₹10.8k Cr
52-week range
₹414.05 – ₹823.3
One year
+54.38%
Price to earnings (TTM to Jun 2026)
35.50×
Return on equity (TTM to Jun 2026)
9.58%

Overview

Symbol
NSE:AKUMS
Exchange
NSE
Currency
INR

What Akums Drugs does

Based on the company's own presentations, annual report and earnings calls.

Akums Drugs and Pharmaceuticals is a Contract Development and Manufacturing Organisation (CDMO) that manufactures formulations and Active Pharmaceutical Ingredients (APIs) for other pharma companies, alongside its own branded formulations (Akumentis) and nutraceutical/wellness products. It operates across the pharmaceutical value chain - developing, manufacturing and supplying tablets, capsules, liquids, injectables, sterile and topical dosage forms - earning revenue mainly from CDMO manufacturing contracts with domestic and multinational pharma clients, supplemented by branded formulation sales, trade generics and API sales. The company is expanding into regulated export markets (Europe) and entered a joint venture with the Government of Zambia to set up a manufacturing plant there.

Segments

  • CDMO
  • Domestic Branded Formulation
  • International Branded Formulation
  • Trade Generics
  • API
Manufacturing facilities
14 (across India)
Annual manufacturing capacity
50.6 billion units
CDMO manufacturing plants
11
API manufacturing plants
3
Total employees (including workers)
18,010
Countries served
70+
Founded 2004Headquarters 304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi – 110034Employees 18,010 (FY2025-26 (as of 31 Marc) Company website

How the price took the results

close before → close after

Q1 FY27
+4.7%
10 Aug
Q4 FY26
+0.5%
18 May
Q3 FY26
+5.7%
16 Feb
Q2 FY26
+3.8%
17 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Akums Drugs

Free account: one company. Everything above stays public.

Write why you follow Akums Drugs and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Akums Drugs

Guides on how to read this kind of business and the numbers that matter.